FI50711C - Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen. - Google Patents

Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.

Info

Publication number
FI50711C
FI50711C FI731543A FI154373A FI50711C FI 50711 C FI50711 C FI 50711C FI 731543 A FI731543 A FI 731543A FI 154373 A FI154373 A FI 154373A FI 50711 C FI50711 C FI 50711C
Authority
FI
Finland
Prior art keywords
corticosteroids
dividing
stereoisomeric mixtures
stereoisomer
components
Prior art date
Application number
FI731543A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI50711B (OSRAM
Inventor
Ralph Lennart Brattsand
Karl Goeran Claeson
Bo Thuresson Af Ekenstam
Bror Arne Thalen
Original Assignee
Bofors Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bofors Ab filed Critical Bofors Ab
Application granted granted Critical
Publication of FI50711B publication Critical patent/FI50711B/fi
Publication of FI50711C publication Critical patent/FI50711C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
FI731543A 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen. FI50711C (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7206645A SE378110B (OSRAM) 1972-05-19 1972-05-19

Publications (2)

Publication Number Publication Date
FI50711B FI50711B (OSRAM) 1976-03-01
FI50711C true FI50711C (fi) 1976-06-10

Family

ID=20269238

Family Applications (1)

Application Number Title Priority Date Filing Date
FI731543A FI50711C (fi) 1972-05-19 1973-05-14 Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.

Country Status (17)

Country Link
US (1) US3928326A (OSRAM)
JP (1) JPS547794B2 (OSRAM)
BE (1) BE799728A (OSRAM)
CA (1) CA1003402A (OSRAM)
CY (1) CY1012A (OSRAM)
DE (1) DE2323216C3 (OSRAM)
DK (1) DK133249C (OSRAM)
FI (1) FI50711C (OSRAM)
FR (1) FR2185406B1 (OSRAM)
GB (1) GB1428416A (OSRAM)
HK (1) HK49079A (OSRAM)
IL (1) IL42154A (OSRAM)
KE (1) KE2969A (OSRAM)
NL (1) NL175917C (OSRAM)
SE (1) SE378110B (OSRAM)
SU (1) SU468408A3 (OSRAM)
ZA (1) ZA732956B (OSRAM)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL188581C (nl) * 1974-07-15 1992-08-03 Akzo Nv Werkwijze voor het bereiden van 11beta-hydroxy-18-alkylestraanverbindingen.
ZA763131B (en) * 1975-05-27 1978-01-25 Syntex Inc Use of flunisolide to treat respiratory diseases
SE8008524L (sv) * 1980-12-04 1982-06-05 Draco Ab 4-pregnen-derivat, ett forfarande for deras framstellning, beredning och metod for behandling av inflammatoriska tillstand
IT1196142B (it) * 1984-06-11 1988-11-10 Sicor Spa Procedimento per la preparazione di 16,17-acetali di derivati pregnanici e nuovi composti ottenuti
SE8604059D0 (sv) * 1986-09-25 1986-09-25 Astra Pharma Prod A method of controlling the epimeric distribution in the preparation of 16,17-acetals of pregnane derivatives
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9100341D0 (sv) * 1991-02-04 1991-02-04 Astra Ab Novel steroids
WO1994015947A1 (en) * 1993-01-08 1994-07-21 Astra Aktiebolag Novel colon- or ileum-specific steroid derivatives
DE19635498A1 (de) * 1996-09-03 1998-03-26 Byk Gulden Lomberg Chem Fab Verfahren zur Epimerenanreicherung
IT1291288B1 (it) 1997-04-30 1999-01-07 Farmabios Srl Processo per la preparazione di 16,17 acetali di derivati pregnanici con controllo della distribuzione epimerica al c-22.
US6266556B1 (en) 1998-04-27 2001-07-24 Beth Israel Deaconess Medical Center, Inc. Method and apparatus for recording an electroencephalogram during transcranial magnetic stimulation
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
JP2007504123A (ja) * 2003-08-29 2007-03-01 ランバクシー ラボラトリーズ リミテッド Ｉｖ型ホスホジエステラーゼの阻害剤
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
WO2005100356A1 (en) 2004-04-09 2005-10-27 Merck & Co., Inc. Inhibitors of akt activity
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
EP1934219A1 (en) 2005-09-16 2008-06-25 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
US20090054382A1 (en) * 2005-10-19 2009-02-26 Abhijit Ray Compositions of phosphodiesterase type iv inhibitors
JP2009512676A (ja) 2005-10-19 2009-03-26 ランバクシー ラボラトリーズ リミテッド ムスカリン性受容体アンタゴニストの医薬組成物
US20110021473A1 (en) * 2006-09-22 2011-01-27 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
KR20120090100A (ko) 2006-12-26 2012-08-16 파마시클릭스, 인코포레이티드 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법
DK2805945T3 (da) 2007-01-10 2019-07-15 Msd Italia Srl Amid-substituerede indazoler som poly(adp-ribose)polymerase- (parp) hæmmere
US20080207659A1 (en) * 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
ES2382715T3 (es) 2007-03-14 2012-06-12 Ranbaxy Laboratories Limited Derivados de pirazol[3,4-B]piridina como inhibidores de fosfodiesterasa
WO2008111009A1 (en) * 2007-03-14 2008-09-18 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
ITMI20080645A1 (it) 2008-04-11 2009-10-12 Ind Chimica Srl Procedimento per la preparazione di budesonide
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
GB0900484D0 (en) 2009-01-13 2009-02-11 Angeletti P Ist Richerche Bio Therapeutic agent
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
BR112012005503B1 (pt) * 2009-09-11 2021-10-13 Chiesi Farmaceutici S.P.A. Derivados de isoxazolidina
GB0916608D0 (en) 2009-09-22 2009-11-04 Angeletti P Ist Richerche Bio Therapeutic compounds
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
US9260417B2 (en) 2010-02-08 2016-02-16 Amitech Therapeutic Solutions, Inc. Therapeutic methods and compositions involving allosteric kinase inhibition
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
EP3330377A1 (en) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
RU2609833C2 (ru) 2011-09-13 2017-02-06 Фармасайкликс Элэлси Лекарственные формы ингибитора гистондиацетилазы в комбинации с бендамутином и их применение
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013305633B2 (en) 2012-08-24 2018-03-08 Board Of Regents, The University Of Texas System Heterocyclic modulators of HIF activity for treatment of disease
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
ME02925B (me) 2012-11-28 2018-04-20 Merck Sharp & Dohme Kompozicije i postupci za liječenje kancera
AU2013361694B2 (en) 2012-12-20 2017-10-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
US11066396B2 (en) 2016-06-23 2021-07-20 Merck Sharp & Dohme Corp. 3-aryl- heteroaryl substituted 5-trifluoromethyl oxadiazoles as histonedeacetylase 6 (HDAC6) inhibitors
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
WO2018089373A2 (en) 2016-11-08 2018-05-17 Regeneron Pharmaceuticals, Inc. Steroids and protein-conjugates thereof
CN110944718A (zh) 2017-05-18 2020-03-31 里珍纳龙药品有限公司 环糊精蛋白质药物偶联物
CA3080857A1 (en) 2017-11-07 2019-05-16 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
MA50259A1 (fr) 2018-01-08 2021-07-29 Regeneron Pharma Stéroïdes et leurs conjugués-anticorps
US11377502B2 (en) 2018-05-09 2022-07-05 Regeneron Pharmaceuticals, Inc. Anti-MSR1 antibodies and methods of use thereof
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
WO2021126729A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Prmt5 inhibitors
PE20251401A1 (es) 2022-09-02 2025-05-22 Merck Sharp And Dohme Llc Inhibidores de topoisomerasa-1 derivados de exatecan composiciones farmaceuticas y sus usos
US20240208987A1 (en) 2022-10-25 2024-06-27 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
PE20252163A1 (es) 2022-12-14 2025-09-04 Merck Sharp And Dohme Llc Enlazadores-cargas utiles de auristatina, composiciones farmaceuticas, y usos de los mismos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133940A (en) * 1956-04-10 1964-05-19 Glaxo Group Ltd Process for the separation of delta-1, 4-3-keto steroid compounds from mixtures thereof with other 3-keto steroids
US3197469A (en) * 1958-08-06 1965-07-27 Pharmaceutical Res Products In 16, 17-acetals and ketals of 6-halo-16, 17-dihydroxy steroids of the pregnane seriesand intermediates therefor
US3048581A (en) * 1960-04-25 1962-08-07 Olin Mathieson Acetals and ketals of 16, 17-dihydroxy steroids
US3128238A (en) * 1962-09-14 1964-04-07 Lilly Co Eli delta1-dehydrogenation of steroids by fermentation with actinoplanaceae

Also Published As

Publication number Publication date
BE799728A (fr) 1973-09-17
NL7306979A (OSRAM) 1973-11-21
AU5525273A (en) 1974-11-07
NL175917C (nl) 1985-01-16
DK133249B (da) 1976-04-12
US3928326A (en) 1975-12-23
SU468408A3 (ru) 1975-04-25
DE2323216B2 (de) 1977-11-03
DE2323216A1 (de) 1973-11-29
JPS547794B2 (OSRAM) 1979-04-10
NL175917B (nl) 1984-08-16
ZA732956B (en) 1974-04-24
CA1003402A (en) 1977-01-11
DE2323216C3 (de) 1978-06-22
FR2185406B1 (OSRAM) 1976-12-31
IL42154A0 (en) 1973-07-30
IL42154A (en) 1976-12-31
HK49079A (en) 1979-07-27
JPS4941379A (OSRAM) 1974-04-18
SE378110B (OSRAM) 1975-08-18
GB1428416A (en) 1976-03-17
DK133249C (da) 1976-09-13
KE2969A (en) 1979-07-20
FI50711B (OSRAM) 1976-03-01
CY1012A (en) 1979-11-23
FR2185406A1 (OSRAM) 1974-01-04

Similar Documents

Publication Publication Date Title
FI50711C (fi) Menetelmä kortikosteroidien stereoisomeeriseosten jakamiseksi stereois omeerikomponenteikseen.
FI51714C (fi) Menetelmä isomaltitolin valmistamiseksi.
YU33073A (en) Process for producing oxazolidine derivatives
JPS52142045A (en) Process for manufacture of cyclopropane derivatives
FI47364C (fi) Menetelmä terapeuttisesti arvokkaiden 3-indolyyli-alifaattinen-happoyh disteiden valmistamiseksi.
CH553782A (fr) Procede de preparation de nouveaux derives de pyridine.
YU3373A (en) Process for obtaining substituted derivatives of piperidinoalkanone-oximes
SE7907064A0 (sv) Förfarande för framställning av naftalenderivat
FI46067C (fi) Menetelmä digitoksigeniiniglykosidien valmistamiseksi.
NL7411242A (nl) Werkwijze ter behandeling van fruit.
FI47575C (fi) Analogiamenetelmä evomonosidi-johdannaisten valmistamiseksi.
FR1394779A (fr) Procédé de nitration en continu de la cellulose
FI44622C (fi) Menetelmä terapeuttisesti arvokkaiden substituoitujen naftaleenijohdan naisten valmistamiseksi.
NO741905L (no) Fremgangsmåte for styring av fremføringen av langstrakte materialstykker.
FI52735C (fi) Menetelmä uusien pregnadieeni-21-happojohdannaisten valmistamiseksi.
SE416952B (sv) Forfarande for framstellning av substituerade fenylamidinokarbamidforeningar
FI50407C (fi) Menetelmä trikloorimonosilaanien valmistamiseksi
FI49841C (fi) Menetelmä amylaasi-inhibiitin valmistamiseksi.
IT1021385B (it) Metodo per isomerizzare destrosio
FI46727C (fi) Menetelmä pyridatsolijohdannaisten valmistamiseksi.
FI49029C (fi) Menetelmä 15alfa,16alfa-metyleeniandrosteenijohdannaisten valmistamise ksi
FI47763C (fi) Menetelmä uusien neriifoliini-johdannaisten valmistamiseksi.
FI52088C (fi) Menetelmä 3-(4-asyylioksialkyyli-1-piperatsinyyli)-karbonyylimetyyli-2 -bentsotiatsolinonijohdannaisten valmistamiseksi.
FI48347C (fi) Menetelmä 17beta-alkanoyylioksi-17alfa-propadienyyli-steroidien valmis tamiseksi.
FI50411C (fi) Menetelmä aryyliamino-2-imidatsoliinien valmistamiseksi